Sep 20th 2012 - Edison Investment Research today published a report on Ablynx entitled "Safe To Inhale". In summary, the report says:
The first clinical trial with an inhaled Nanobody has been successfully completed. ALX-0171, developed to treat respiratory syncytial virus (RSV) infections, was well tolerated and no immunogenicity was detected. Additional Phase I studies are planned before the Nanobody enters paediatric Phase II development, and Ablynx aims to partner the product before then. These results further highlight the potential of Nanobodies, as monoclonal antibodies cannot be delivered in a similar way.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »
